Huntsman Q2 Loss Narrows Sharply, but Breakeven Adjusted Results Keep Recovery Uncertain

What happened

Huntsman reported a substantially narrowed Q2 2026 net loss of $6 million, compared to a $158 million loss a year earlier, with adjusted EPS breaking even versus a loss of $0.20 per share. The improvement suggests that restructuring efforts and cost controls are beginning to offset the prolonged cyclical downturn in core chemical markets. However, the company remains essentially at breakeven on an adjusted basis, with elevated leverage and negative interest coverage still posing risks. While the results are a step in the right direction, they do not yet provide a clear margin of safety or a definitive turn in the earnings cycle. The wait-and-see stance from the prior deep value analysis remains appropriate, with a focus on sustained operational recovery and further de-levering.

Implication

The narrowed loss and breakeven adjusted earnings indicate restructuring may be gaining traction, yet the company is still in a fragile state with high debt. Investors should watch for consecutive quarters of positive adjusted earnings and declining leverage before considering a position. The stock may remain range-bound until there is clearer evidence of a durable recovery.

Thesis delta

The Q2 2026 earnings improvement reduces near-term downside risk but does not alter the core thesis that Huntsman is a cyclical recovery play with an inadequate margin of safety at current levels. The results inch the company closer to a potential buy signal, but the watch items—sustained operational recovery and leverage reduction—remain critical.